These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3686044)

  • 1. Impact of dose-intense chemotherapy on the development of permanent drug resistance.
    Coldman AJ; Goldie JH
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):29-33. PubMed ID: 3686044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic modeling of drug resistance in cancer.
    Komarova N
    J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in cancer therapeutics: chemotherapy.
    DeVita VT
    Prog Clin Biol Res; 1983; 132A():47-69. PubMed ID: 6634746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling chemotherapy resistance in palliation and failed cure.
    Monro HC; Gaffney EA
    J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to adjuvant chemotherapy for breast cancer.
    Hudis C
    Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of theoretical models to chemotherapy protocol design.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1986 Jan; 70(1):127-31. PubMed ID: 3510731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1979; 63(11-12):1727-33. PubMed ID: 526911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the use of alternating non-cross-resistant chemotherapy.
    Goldie JH; Coldman AJ; Gudauskas GA
    Cancer Treat Rep; 1982 Mar; 66(3):439-49. PubMed ID: 7060033
    [No Abstract]   [Full Text] [Related]  

  • 9. Modeling toxicity and response in carboplatin-based combination chemotherapy.
    Egorin MJ; Reyno LM; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):7-19. PubMed ID: 7992070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current developments in chemotherapy of advanced testicular tumors].
    Schmoll HJ; Seeber S
    Urologe A; 1993 May; 32(3):207-16. PubMed ID: 8511834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of drug resistance.
    Sobrero A; Bertino JR
    Cancer Surv; 1986; 5(1):93-107. PubMed ID: 3297314
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D; Jelić S; Radulović S
    Srp Arh Celok Lek; 2000; 128(3-4):75-9. PubMed ID: 10932613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity.
    Yoon SY; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Acta Haematol; 2007; 118(1):30-7. PubMed ID: 17429195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.
    Uchida J; Okabe H; Nakano K; Fujioka A; Saito H; Sugimoto Y; Oka T; Fukushima M
    Oncol Rep; 2007 Aug; 18(2):313-9. PubMed ID: 17611650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Average relative dose intensity and the impact on design of clinical trials.
    Hryniuk WM
    Semin Oncol; 1987 Mar; 14(1):65-74. PubMed ID: 3823917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.